26 completed, 4 unknown, 2 recruiting, 2 withdrawn. 35 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Completed 26, Unknown 4, Recruiting 2, Withdrawn 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Recruiting | Telios Pharma, Inc. | 60 | 2025-10-23 | 2025-11-25 |
| Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Recruiting | Telios Pharma, Inc. | 66 | 2024-10-03 | 2024-11-13 |
| A Study Of TL-925 For The Treatment of AC TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Completed | Telios Pharma, Inc. | 80 | 2024-04-11 | 2024-07-03 |
| A Study of TL-925 for the Treatment of Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Unknown | Telios Pharma, Inc. | 70 | 2023-11-01 | 2023-12-01 |
| Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies VSJ-110, Placebo - Allergic Conjunctivitis | Phase 2 | Completed | Vanda Pharmaceuticals | 47 | 2020-11-21 | 2025-09-11 |
| Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis Eye Drops, Solution in Single-Dose Container - Allergic Conjunctivitis, Allergic Rhinitis | Phase 2 | Completed | Marinomed Biotech AG | 64 | 2020-08-04 | 2022-08-25 |
| Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Intra-lymphatic allergenic extract, Intra-lymphatic placebo - Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis | Phase 2 | Completed | Christopher Thompson, MD | 21 | 2018-09-28 | 2021-04-20 |
| A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 1 / Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 52 | 2018-09-08 | 2025-04-08 |
| Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis PR013 (0.045%), PR013 (0.06%), Vehicle - Allergic Conjunctivitis | Phase 2 | Completed | Realm Therapeutics, Inc. | 96 | 2017-12-10 | 2020-01-29 |
| Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis PRT-2761 0.5%, PRT-2761 1%, Patanol - Allergic Conjunctivitis | Phase 2 | Completed | ORA, Inc. | 120 | 2017-10-13 | 2022-10-17 |
| A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6% - Allergic Conjunctivitis | Phase 2 | Completed | Faes Farma, S.A. | 121 | 2017-07-20 | 2023-03-16 |
| Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis ST266, Saline (0.9% NaCl) - Allergic Conjunctivitis | Phase 2 | Completed | Noveome Biotherapeutics, formerly Stemnion | 70 | 2016-12-01 | 2023-04-10 |
| A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%) - Allergic Conjunctivitis, Seasonal Allergies | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 100 | 2015-08-01 | 2023-12-05 |
| Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1% - Allergic Conjunctivitis | Phase 2 | Completed | Alcon Research | 224 | 2014-04-01 | 2015-08-24 |
| A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) Active Comparator EBI-005 5 mg/mL, Placebo Comparator - Allergic Conjunctivitis | Phase 2 | Completed | Eleven Biotherapeutics | 150 | 2014-02-01 | 2014-07-11 |
| Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis hydrocortisone ophthalmic ointment 0.5%, placebo - Allergic Conjunctivitis | Phase 2 | Terminated | Koffler Vision Group | 15 | 2013-05-01 | 2017-08-18 |
| The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions Allergen(Tree, Grass, Weeds) - Allergic Rhinitis, Asthma | Phase 1 / Phase 2 | Unknown | University Hospitals Cleveland Medical Center | 245 | 2013-04-01 | 2013-06-17 |
| AGN-229666 for the Treatment of Allergic Conjunctivitis AGN-229666, vehicle of AGN-229666 - Allergic Conjunctivitis | Phase 2 | Completed | Allergan | 90 | 2012-10-01 | 2014-02-04 |
| Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis RX-10045, Vehicle for RX-10045 arm - Allergic Conjunctivitis | Phase 2 | Completed | C.T. Development America, Inc. | 60 | 2012-07-01 | 2013-02-08 |
| Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis SPARC1102 I, SPARC1102 II, SPARC1102 III - Allergic Conjunctivitis | Phase 2 | Completed | Sun Pharma Advanced Research Company Limited | 122 | 2011-06-01 | 2016-06-24 |
Showing 20 of 35. Sign in to see all of them.
Conjunctivitis, Allergic (35) · Conjunctivitis (4) · Rhinitis, Allergic, Seasonal (4) · Hypersensitivity (3) · Rhinitis, Allergic (3) · Asthma (2) · Dermatitis, Atopic (1) · Food Hypersensitivity (1) · Lacerations (1)
Conjunctival Diseases (35) · Eye Diseases (35) · Hypersensitivity, Immediate (35) · Immune System Diseases (35) · Hypersensitivity (32) · Conjunctivitis (31) · Nose Diseases (6) · Otorhinolaryngologic Diseases (6) · Respiratory Hypersensitivity (6) · Respiratory Tract Diseases (6) · Rhinitis (6) · Rhinitis, Allergic (3) · Bronchial Diseases (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2)
Dexamethasone (3) · Ketotifen (2) · Methylprednisolone (2) · BID protein, human (1) · Lubricant Eye Drops (1) · Ointments (1) · Olopatadine Hydrochloride (1) · Ophthalmic Solutions (1) · Sodium Chloride (1) · Solutions (1) · Tacrolimus (1) · Transdermal Patch (1) · Vasoconstrictor Agents (1) · bilastine (1) · isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (1)
Telios Pharma, Inc. (4) · Alcon Research (3) · Bausch & Lomb Incorporated (3) · Aciex Therapeutics, Inc. (2) · Aldeyra Therapeutics, Inc. (2) · Faes Farma, S.A. (2) · Fovea Pharmaceuticals SA (2) · Allergan (1) · Assaf-Harofeh Medical Center (1) · C.T. Development America, Inc. (1) · Christopher Thompson, MD (1) · Eleven Biotherapeutics (1) · Eye Therapies, LLC (1) · Koffler Vision Group (1) · Marinomed Biotech AG (1)
United States (25) · Canada (2) · Austria (1) · Finland (1) · Israel (1) · Japan (1)
Gail L Torkildsen, MD (2) · Gail Torkildsen, MD (2) · Alessandra Cesano, MD (1) · Ander Sologuren, MD (1) · Christopher Thompson, MD (1) · David Zadok, MD (1) · Devi K Jhaveri, D.O. (1) · Erkki Savilahti, Professor (1) · Eva Prieschl-Grassauer, PhD (1) · Haig Tcheurekdjian, M.D. (1) · Jean-Philippe Combal, PharmD (1) · Marie-Louise Jacques, MD MBA (1) · Michael Goldstein, MD (1)
PMID 18595980, PMID 21771118, PMID 22093109, PMID 23484763, PMID 28007090, PMID 30326954, PMID 30472801, PMID 32407947, PMID 34857814, PMID 35585427, PMID 37438187, PMID 38687061, PMID 39386177
2019 (1)